The FDA lists an ongoing Class III recall of olanzapine 5 mg tablets in 30-count bottles made by Macleods Pharmaceuticals for the US market. The reason given is organic and unspecified impurities above specification.
Class III is the lowest recall category: use of the product is unlikely to cause harm. This is a manufacturing quality action, not a new safety finding about olanzapine.
The recall applies to US-distributed lots. Whether any Indian supply is affected is not stated, and CDSCO has issued no linked notice that we are aware of.
No patient should stop olanzapine because of this notice. Abrupt withdrawal risks relapse and discontinuation symptoms, which outweigh the hazard of a Class III impurity issue.
- Do not advise patients to stop olanzapine because of this recall
- Class III means harm from the affected product is unlikely
- The notice concerns one manufacturer's US-labelled 5 mg tablets
- If a patient raises it, reassure and check the supplier with the dispensing pharmacy
Why it matters
Recall headlines can trigger unplanned antipsychotic stops, which carry far more risk than the defect.
Don't overread it
A Class III impurity recall is a manufacturing issue, not evidence that olanzapine is less safe.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for psychiatry, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free